Faron

We are pleased to announce Faron has joined a research consortium that has received a United States Department of Defense (DoD) Grant to investigate the use of Traumakine®, our intravenous interferon beta-1a therapy, in preventing ischemia-reperfusion injury in battlefield victims when using a lifesaving torniquet. To read more, visit: https://lnkd.in/eKub9r7r   #Faron #Biotech #drugdevelopment

We are thrilled to announce the appointment of Yrjö E K Wichmann, Faron’s current interim CFO, as our permanent CFO.   Yrjö previously served as our CFO between 2014-2019, and his in-depth knowledge of the Company alongside his critical expertise as an accomplished biotech and financial executive with over 20 years of experience in financing and investment banking will continue to play a pivotal role in strengthening the Company and advancing #bexmarilimab, our proprietary immunotherapy asset.   Press release here: https://lnkd.in/eYUSAZTy   #Appointment #Faron #Biotech #drugdevelopment #oncology

We are delighted to welcome Dr. Petri Bono to Faron as our new Chief Medical Officer. Dr. Bono will succeed Dr. Birge Berns, MD, MRCP, FFPM, who will continue her role as part of Faron’s medical leadership team involved in developing #bexmarilimab.   Dr. Bono’s translational and clinical studies in targeted therapies and applied immunology will be invaluable in supporting Faron's immuno-oncology program and progressing our wholly-owned immunotherapy asset, #bexmarilimab, to a broader patient population.   To read the full press release, please visit: https://lnkd.in/eJ3MX98r   #Appointment #Faron #Biotech #drugdevelopment #oncology

We’re #hiring. Join our team to make a difference! Interested and confident you could be the person we are looking for? Please send us your cover letter and CV in English by 1st September. https://lnkd.in/dUT_8PcF

We are delighted to be featured in LA Weekly. The article outlines Faron’s journey so far in developing #bexmarilimab, Faron’s humanized monoclonal antibody to overcome treatment resistance in both hematological malignancies and solid tumors, highlighting our differentiated mode of action and accelerated approval plans on the back of recent positive FDA feedback.   To read the article, visit: https://lnkd.in/dwkv3Y6A   #Faron #biotech #drugDevelopment

Great to see our recent positive FDA feedback regarding #bexmarilimab featured in the Daily Mail!   This is further recognition of the promising potential of our wholly-owned immunotherapy asset and highlights our commitment of advancing promising new cancer treatments to a broader patient population as early as possible.   Read the article here: https://lnkd.in/ePyZf935   #Faron #biotech #drugdevelopment

Today we announced positive feedback from the US FDA, regarding the registrational study plan for #bexmarilimab, our wholly owned #immunotherapy candidate, in treating myelodysplastic syndrome (MDS) patients that have failed a hypomethylating agent (HMA), also known as relapsed/refractory MDS (r/r MDS). The FDA proposed that instead of moving into a randomized registrational Phase 3 study, Faron conduct a confirmatory Phase 3 study in frontline high-risk MDS (HR MDS), that would not require a separate Phase 3 in r/r MDS. The Phase 3 suggested by the FDA targets a significantly larger patient population with potential for faster approval earlier than anticipated, speeding up and increasing our sales forecast for bexmarilimab. This FDA guidance is part of Project Frontrunner, an initiative intended to bring promising new cancer treatments as early as possible to a broader patient population. To read the full press release, visit: https://lnkd.in/dB7mv8Ju #Faron #biotech #drugdevelopment 

Faron’s EUR 30.7 million public offering has ended successfully and was oversubscribed – a warm thank you to everyone who participated. #bexmarilimab #immunotherapy #biotech #drugDevelopment

Activate your body to deactivate cancer - Join us in transforming blood cancer care: Faron organizes a share issue on 5 – 18 June 2024. Get to know the company in the webinar on 6 June 2024 at 19:00 hrs. Offering Circular, additional Information and webinar registration: www.faron.com/publicoffer

#ICYMI last week we hosted a webinar to discuss the recent positive results from the Phase 2 part of our ongoing BEXMAB study, investigating #bexmarilimab, our wholly owned #immunotherapy candidate, in myelodysplastic syndrome (MDS) patients that have failed a hypomethylating agent (HMA), also known as relapsed/refractory MDS (r/r MDS).   Thank you to Juho Jalkanen MD, PhD, our CEO, Dr. Amer Zeidan, Associate Professor of Medicine (Hematology) at Yale University and Tuomo Pätsi, our Chairman for providing their insights into these promising data and the potential of #bexmarilimab to fill a very important clinical gap in the management of MDS patients.   To watch the full recording, visit: https://lnkd.in/eRyR-_pT   #Faron #bexmarilimab #biotech #drugDevelopment